Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 2
2009 5
2010 3
2011 2
2012 4
2013 4
2014 3
2015 5
2016 8
2017 3
2018 8
2019 11
2020 9
2021 8
2022 14
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
Réa D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D'Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A. Réa D, et al. Among authors: minami y. Leukemia. 2023 May;37(5):1060-1067. doi: 10.1038/s41375-023-01888-y. Epub 2023 Apr 14. Leukemia. 2023. PMID: 37069326 Free PMC article. Clinical Trial.
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01.
Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y; All HM-SCREEN-Japan 01 Investigators. Hosono N, et al. Among authors: minami y. Cancer Sci. 2023 May;114(5):2098-2108. doi: 10.1111/cas.15746. Epub 2023 Mar 1. Cancer Sci. 2023. PMID: 36793248 Free PMC article.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Hochhaus A, et al. Among authors: minami y. Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717654 Free PMC article. Clinical Trial.
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D. Atallah E, et al. Among authors: minami y. J Cancer Res Clin Oncol. 2023 Aug;149(9):6247-6262. doi: 10.1007/s00432-022-04562-5. Epub 2023 Jan 28. J Cancer Res Clin Oncol. 2023. PMID: 36707445 Free PMC article.
91 results